PMOS: Kaletra Tolerability

Trial Profile

PMOS: Kaletra Tolerability

Phase of Trial: Phase IV

Latest Information Update: 26 May 2017

At a glance

  • Drugs Lopinavir/ritonavir (Primary) ; Non-nucleoside reverse transcriptase inhibitors; Peptide hydrolase inhibitors
  • Indications HIV infections
  • Focus Therapeutic Use
  • Acronyms PMOS
  • Sponsors Abbott Laboratories; AbbVie
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 04 Feb 2016 Status changed from active, no longer recruiting to completed as reported by record.
    • 21 May 2015 Planned number of patients changed from 3000 to 3200, according to record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top